The global biodegradable stents market size was valued at USD 442.17 million in 2025 and is projected to grow from USD 476.62 million in 2026 to USD 868.55 million by 2034, registering a CAGR of 7.79% during the forecast period from 2026 to 2034. North America dominated the biodegradable stents market with a market share of 38.6% in 2025.
Biodegradable stents are temporary medical implants used to keep blocked or narrowed blood vessels open and gradually dissolve after the vessel has healed. These stents are typically made from bioresorbable polymers or biodegradable metal alloys that provide structural support during recovery and then naturally break down within the body over time. By eliminating the need for a permanent implant, biodegradable stents help reduce long-term complications associated with traditional metal stents and support the restoration of normal vascular function.
Download a Free Sample To learn more about this report,
Magnesium-Based Bioresorbable Stents Are Advancing Temporary Vascular Support
The biodegradable stents market trends show that the need for temporary vascular support is shifting stent development toward magnesium-based bioresorbable materials that provide mechanical support before gradually degrading inside the body. This transition is reducing the long-term presence of permanent metallic implants while supporting vessel healing and restoration. The result is greater attention to magnesium-based scaffolds as an alternative for selected coronary interventions.
Ultra-Thin Strut Designs Are Improving Biodegradable Stent Performance
The biodegradable stents market trends show that concerns related to scaffold thickness, blood flow, and procedural delivery are shifting product development toward ultra-thin strut scaffold designs. This transition supports easier stent delivery, lower vessel disturbance, and improved blood-flow characteristics while maintaining the mechanical support required during healing. The result is a focus on thinner biodegradable scaffolds that can improve procedural performance and vascular outcomes.
Preference for Temporary Vascular Support and Cardiovascular Device Innovation Drive Market
Preference for treatment options that provide temporary vessel support is strengthening demand for biodegradable stents. These devices provide structural support during vascular healing and gradually break down after serving their intended function, reducing the duration of permanent material within the artery. Applications in selected coronary interventions create demand for biodegradable stent technologies among physicians seeking temporary scaffolding options.
Investment in cardiovascular device innovation is strengthening the development and supply of advanced biodegradable stents. Research efforts support improvements in scaffold performance, drug delivery, and manufacturing precision, while clinical development programs help bring new products toward commercialization. Continued innovation by medical device companies therefore creates additional supply opportunities and broadens the range of biodegradable stent technologies available for cardiovascular procedures.
High Costs and Biodegradation Complexity Restrain Biodegradable Stents Market Expansion
High costs of biodegradable stent technologies stem from specialized biomaterials, advanced manufacturing processes, and extensive testing requirements. Higher production and device costs can increase the financial burden on hospitals and patients, especially where reimbursement is limited. This cost pressure can restrict adoption and slow the shift from established permanent stent technologies.
Complex biodegradation control requires precise management of the stent’s degradation rate while maintaining sufficient mechanical support during vessel healing. Variations in material degradation can affect structural integrity, drug release, and treatment outcomes, increasing development and quality-control requirements. These technical challenges can raise development risks and limit the wider adoption of biodegradable stents.
Drug-Eluting Bioresorbable Stents and Emerging-Market Adoption Create New Market Opportunities
Interventional cardiology centres, pharmaceutical companies, and medical-device manufacturers can benefit from drug-eluting bioresorbable stents that combine temporary vessel support with localized drug delivery. Companies such as Abbott and BIOTRONIK have experience in drug-eluting and bioresorbable stent technologies, creating revenue through differentiated scaffold-drug combinations, premium devices, and licensing opportunities while supporting biodegradable stents market growth.
Medical-device manufacturers, local distributors, and hospitals in emerging economies can benefit from cost-effective biodegradable stents and stronger regional supply networks. Companies such as Meril Life Sciences can leverage cardiovascular-device manufacturing capabilities and local partnerships to generate revenue through regional sales, hospital contracts, and localized production while supporting biodegradable stents market growth.
Limited Long-Term Clinical Evidence and Established Drug-Eluting Stent Competition Hinder Biodegradable Stents Market Growth
Limited long-term clinical evidence makes it difficult for companies to establish the durability and safety of biodegradable stents after complete scaffold degradation. Uncertainty around long-term vessel outcomes can increase physician caution, slow hospital procurement, and extend the time required for newer products to achieve broader clinical adoption. For example, Abbott discontinued its Absorb bioresorbable vascular scaffold after concerns regarding clinical outcomes limited its commercial uptake.
Strong competition from established drug-eluting stents creates another challenge because metallic stents have extensive clinical experience, established procedural workflows, and broad physician familiarity. This entrenched market position makes it difficult for biodegradable stent manufacturers to demonstrate sufficient differentiation and secure wider hospital adoption.
The polymer based segment dominated the biodegradable stents market with a market share of 58.4% in 2025 and is also expected to grow at the fastest CAGR of 8.85% during the forecast period 2026–2034. Polymer-based biodegradable stents are designed to provide temporary vascular support while the material gradually degrades after implantation.
The biodegradable stents segment represents products designed to provide temporary vascular support, while the metal based biodegradable stents segment uses degradable metals in stent construction. These product categories offer different approaches to vascular scaffolding based on material properties and degradation characteristics.
Request Customizationto receive a tailored report.
The coronary artery disease segment dominated the biodegradable stents market with a market share of 72.6% in 2025 and is also expected to grow at the fastest CAGR of 8.55% during the forecast period 2026–2034. The coronary artery disease segment covers stent applications intended to help restore and maintain blood flow through narrowed coronary arteries.
The peripheral artery disease segment represents another application area for biodegradable stents, particularly in procedures involving narrowed or blocked peripheral blood vessels. This segment supports interventions aimed at restoring blood flow in vessels outside the heart.
The intermediate absorption rate segment dominated the biodegradable stents market with a market share of 46.2% in 2025 and is also expected to grow at the fastest CAGR of 8.75% during the forecast period 2026–2034. The intermediate absorption rate segment is designed to provide vascular support for a defined period before the stent material gradually degrades and is absorbed by the body.
The slow absorption rate segment is designed to maintain vascular support for a longer period, while the fast absorption rate segment is intended to degrade over a shorter duration. These absorption profiles address different requirements for the duration of temporary vascular support.
The hospital segment dominated the biodegradable stents market with a market share of 68.9% in 2025, supported by the availability of cardiovascular departments, catheterization facilities, and trained clinical teams. The cardiac centers segment also represents an important end-user category for specialized cardiovascular interventions.
The cardiac centers segment is expected to grow at the fastest CAGR of 8.7% during the forecast period 2026–2034. The hospital segment provides broader facilities for cardiovascular procedures, while the cardiac centers segment focuses on specialized cardiac diagnosis, treatment, and intervention.
Speak to an Analystto discuss market opportunities.
The North America biodegradable stents market analysis accounted for the largest regional share of 38.6% in 2025. The region benefits from advanced cardiac care facilities, established interventional cardiology services, and greater access to innovative vascular treatment technologies. The U.S. biodegradable stents market analysiscould benefit from the projected increase in cardiovascular disease, with the American Heart Association estimating that more than 184 million people, or over 61% of the U.S. population, could have some form of cardiovascular disease by 2050, while cardiovascular disease excluding hypertension could increase from 28 million to 45 million adults.
The Canada biodegradable stents market analysis is supported by demographic changes, as Statistics Canada projects the share of Canadians aged 65 and older to increase from 19.5% in 2025 to 22.6%-32.5% by 2075, while the population aged 85 and older is also expected to increase substantially, creating greater long-term demand for cardiovascular care and related interventions.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe biodegradable stents market is projected to register a CAGR of 9.35% during the forecast period 2026–2034, making it the fastest-growing regional market. The region benefits from established healthcare systems, specialized cardiovascular services, and continued interest in advanced vascular treatment options. The U.K. biodegradable stents market could see continued demand for cardiovascular interventions as British Heart Foundation modelling projects 1.5 million more people aged 60–74 in England by 2035, while annual premature cardiovascular disease deaths could reach 44,000 by 2035 if the 2022 premature death rate remains unchanged.
The Germany biodegradable stents market could benefit from demographic ageing, with Germany’s Federal Statistical Office projecting that one in four people will be aged 67 or older by 2035, while the number of people aged 80 and above is projected to increase from 6.1 million in 2024 to around 8.5–9.8 million by 2050.
The France biodegradable stents market could be supported by an ageing population, as France’s INSEE projects that people aged 75 and older will account for 14.8% of the population by 2040, compared with 12.3% in 2030, increasing the potential need for cardiovascular care among older adults.
The Asia Pacific biodegradable stents market accounted for a 22.8% regional share in 2025 and is projected to register a CAGR of 8.75% during the forecast period 2026–2034. The region benefits from improving cardiovascular care infrastructure, wider access to minimally invasive procedures. The Japan biodegradable stents market could be supported by demographic ageing, as Japan’s Ministry of Health, Labour and Welfare projects that people aged 65 and older will account for about 35% of the population by 2040, while the population aged 75 and older is expected to remain substantial, increasing the need for cardiovascular care and related interventions.
The China biodegradable stents market could see greater demand for cardiovascular interventions as the UN projects that the number of people aged 65 and older will nearly double between 2023 and 2050, with this age group potentially accounting for around 30% of China's total population by 2050.
The South Korea biodegradable stents market could benefit from continued population ageing, with Statistics Korea projecting households headed by people aged 65 and older to increase from 4.64 million in 2020 to 11.38 million in 2050, raising the need for age-related healthcare and cardiovascular treatment.
The India biodegradable stents market could gain from the country's ageing demographic, as the UN projects that the number of people aged 65 and older will more than double between 2023 and 2050, increasing pressure on healthcare systems and the need for cardiovascular care.
The biodegradable stents market competitive landscape is moderately fragmented, with competition comprising global medical device manufacturers, cardiovascular technology companies, specialized stent developers, and emerging medical device firms. Key players such as Abbott Laboratories, Biotronik, Reva Medical, Elixir Medical Corporation, and Arterius Limited are among the prominent participants in the biodegradable stents market share.
Established players compete primarily on stent design, biodegradation performance, clinical evidence, safety, radial strength, drug-delivery capabilities, regulatory approvals, manufacturing expertise, and established hospital relationships. Emerging and specialized players in the biodegradable stents market ecosystem compete through innovative biodegradable materials, improved biocompatibility, customized stent designs, minimally invasive delivery systems, and cost-efficient manufacturing approaches that support differentiated clinical applications.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
General Surgical Devices Market Size, Share, Growth, Analysis, 2034
Bioresorbable Coronary Scaffolds Market Size, Forecast, Demand, 2034
Germany Surgical Equipment Market Size, Share and Forecast to 2034
Europe Surgical Equipment Market Size, Top Share and Forecast to 2034
Plasmapheresis Machines Market Size, Share, Growth, Analysis, 2034
Facial Cleansing Devices Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com